

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 December 2024 (19.12.2024)



(10) International Publication Number
WO 2024/259279 A3

(51) International Patent Classification:

C12N 15/86 (2006.01) *A61K 48/00* (2006.01)
A61K 31/711 (2006.01) *C07K 16/18* (2006.01)

(21) International Application Number:

PCT/US2024/034072

(22) International Filing Date:

14 June 2024 (14.06.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/508,169 14 June 2023 (14.06.2023) US

(71) Applicant: **INTERIUS BIOTHERAPEUTICS, INC.**
[US/US]; 3401 Grays Ferry Avenue, Building 200, Suite
300, Philadelphia, Pennsylvania 19146 (US).

(72) Inventors: **BORAL, Debasish**; c/o Interius Biotherapeu-
tics, Inc., 3401 Grays Ferry Avenue, Building 200, Suite
300, Philadelphia, Pennsylvania 19146 (US). **SCHNEPP,**

Bruce C.; c/o Interius Biotherapeutics, Inc., 3401 Grays
Ferry Avenue, Building 200, Suite 300, Philadelphia, Penn-
sylvania 19146 (US). **JOHNSON, Philip R.**; c/o Interius
Biotherapeutics, Inc., 3401 Grays Ferry Avenue, Building
200, Suite 300, Philadelphia, Pennsylvania 19146 (US).

(74) Agent: **ZHANG, Clark** et al.; Goodwin Procter LLP, 100
Northern Avenue, Boston, Massachusetts 02210 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(54) Title: PSEUDOTYPED VIRAL PARTICLES COMPRISING ENGINEERED CHIMERIC RECEPTOR PROTEINS




FIG. 1A

(57) Abstract: Provided for herein are viral particles comprising a heterologous viral glycoprotein and a targeting moiety, wherein the targeting moiety comprises a polypeptide comprising a formula of T-S₁, wherein T is a target binding domain and S₁ is a stalk portion. As provided for herein, the viral particles further comprises a nucleic acid molecule encoding for a heterologous molecule of interest. As provided for herein, the heterologous molecule of interest may be a tandem CAR. Also provided for herein are compositions comprising the same, and methods of using the same.

[Continued on next page]

WO 2024/259279 A3

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(88) Date of publication of the international search report:
15 May 2025 (15.05.2025)

(15) Information about Correction:
see Notice of 10 April 2025 (10.04.2025)